– Biogen Idec will commercialize fampridine prolonged release tablet a prolonged release tablet in markets outside the U.S. For people with MS, impaired walking ability is one of the most common and most difficult aspects of the disease, said Alfred Sandrock, Senior Vice President, Neurology Research and development, Biogen Idec. AMPYRA may be an important therapy in reducing the effects of this debilitating condition. – We congratulate our partner, Acorda Therapeutics, on this important achievement and forward to working with regulators outside the United States this treatment for all people with MS make.
This new data provide strong evidence patients manipulation of one or more migraine trigger sites can successfully eliminate or the frequency, duration and / or intensity of migraine headaches with lasting results. – Bahman Guyuron, chairman of Plastic Surgery at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, and an internationally recognized leader in the field of plastic surgery to new five-year research data that may to show could have a cure for migraine headaches on 24 October 2009, Annual Meeting of the American Society of Plastic Surgeons in Seattle..